Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Hypoxia-inducible factors: cancer progression and clinical translation
Elizabeth E. Wicks, Gregg L. Semenza
Elizabeth E. Wicks, Gregg L. Semenza
Published June 1, 2022
Citation Information: J Clin Invest. 2022;132(11):e159839. https://doi.org/10.1172/JCI159839.
View: Text | PDF
Review Article has an altmetric score of 23

Hypoxia-inducible factors: cancer progression and clinical translation

  • Text
  • PDF
Abstract

Hypoxia-inducible factors (HIFs) are master regulators of oxygen homeostasis that match O2 supply and demand for each of the 50 trillion cells in the adult human body. Cancer cells co-opt this homeostatic system to drive cancer progression. HIFs activate the transcription of thousands of genes that mediate angiogenesis, cancer stem cell specification, cell motility, epithelial-mesenchymal transition, extracellular matrix remodeling, glucose and lipid metabolism, immune evasion, invasion, and metastasis. In this Review, the mechanisms and consequences of HIF activation in cancer cells are presented. The current status and future prospects of small-molecule HIF inhibitors for use as cancer therapeutics are discussed.

Authors

Elizabeth E. Wicks, Gregg L. Semenza

×

Total citations by year

Year: 2025 2024 2023 2022 2009 Total
Citations: 70 104 62 6 1 243
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2023 (62)

Title and authors Publication Year
Conditional Knockout of Hypoxia-Inducible Factor 1-Alpha in Tumor-Infiltrating Neutrophils Protects against Pancreatic Ductal Adenocarcinoma
Sieow JL, Penny HL, Gun SY, Tan LQ, Duan K, Yeong JP, Pang A, Lim D, Toh HC, Lim TK, Engleman E, Rotzschke O, Ng LG, Chen J, Tan SM, Wong SC
International journal of molecular sciences 2023
Aberrant Expression of Solute Carrier Family 35 Member A2 Correlates With Tumor Progression in Breast Cancer
LIU CL, CHENG SP, HUANG WC, CHEN MJ, LIN CH, CHEN SN, CHANG YC
In vivo (Athens, Greece) 2023
Iron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic Targets
Sawicki KT, De Jesus A, Ardehali H
Circulation research 2023
“Pulsed Hypoxia” Gradually Reprograms Breast Cancer Fibroblasts into Pro-Tumorigenic Cells via Mesenchymal–Epithelial Transition
Nushtaeva A, Ermakov M, Abdurakhmanova M, Troitskaya O, Belovezhets T, Varlamov M, Gayner T, Richter V, Koval O
International journal of molecular sciences 2023
Correlation between the Warburg effect and progression of triple-negative breast cancer
Liu S, Li Y, Yuan M, Song Q, Liu M
Frontiers in Oncology 2023
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen Z, Han F, Du Y, Shi H, Zhou W
Signal Transduction and Targeted Therapy 2023
Comparison of Characterization in Two-Dimensional and Three-Dimensional Canine Mammary Gland Tumor Cell Models
Osaki T, Sunden Y, Warita K, Okamoto Y
2023
Lipids as Targets for Renal Cell Carcinoma Therapy
Stepanovska Tanturovska B, Manaila R, Fabbro D, Huwiler A
International journal of molecular sciences 2023
The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies
Melaiu O, Vanni G, Portarena I, Pistolese CA, Anemona L, Pomella S, Bei R, Buonomo OC, Roselli M, Mauriello A, Barillari G
International journal of molecular sciences 2023
Transcriptional Response to Hypoxia: The Role of HIF-1-Associated Co-Regulators.
Yfantis A, Mylonis I, Chachami G, Nikolaidis M, Amoutzias GD, Paraskeva E, Simos G
Cells 2023
Ferroptosis Regulated by Hypoxia in Cells
Zheng X, Liang Y, Zhang C
Cells 2023
The role of lipid metabolic reprogramming in tumor microenvironment
Yang K, Wang X, Song C, He Z, Wang R, Xu Y, Jiang G, Wan Y, Mei J, Mao W
Theranostics 2023
Telomerase deficiency and dysfunctional telomeres in the lung tumor microenvironment impair tumor progression in NSCLC mouse models and patient-derived xenografts.
Piñeiro-Hermida S, Bosso G, Sánchez-Vázquez R, Martínez P, Blasco MA
Cell Death and Differentiation 2023
Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
Lun J, Zhang H, Guo J, Yu M, Fang J
Frontiers in pharmacology 2023
Long-term treatment of chronic kidney disease patients with anemia using hypoxia-inducible factor prolyl hydroxylase inhibitors: potential concerns.
He J, Jia Z, Zhang A, Bai M
Pediatric nephrology (Berlin, Germany) 2023
EPAS1/HIF-2α Acts as an Unanticipated Tumor-Suppressive Role in Papillary Thyroid Carcinoma
Zhang R, Zhao J, Zhao L
International journal of general medicine 2023
Correlation between peripheral blood hemoglobin/erythrocyte distribution width ratio and prognosis of patients with primary colorectal cancer
Li K, Yan J, Zhang H
Medicine 2023
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology.
Bolshette N, Ibrahim H, Reinke H, Asher G
Nature reviews. Gastroenterology & hepatology 2023
Hypoxia induced responses are reflected in the stromal proteome of breast cancer.
Kjølle S, Finne K, Birkeland E, Ardawatia V, Winge I, Aziz S, Knutsvik G, Wik E, Paulo JA, Vethe H, Kleftogiannis D, Akslen LA
Nature Communications 2023
Understanding human aging and the fundamental cell signaling link in age-related diseases: the middle-aging hypovascularity hypoxia hypothesis
Phua TJ
2023
Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp
Hijazi MA, Gessner A, El-Najjar N
Cancers 2023
Roles of circRNA dysregulation in esophageal squamous cell carcinoma tumor microenvironment
Li J, Song Y, Cai H, Zhou B, Ma J
Frontiers in Oncology 2023
Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies
Pinto E, Pelizzaro F, Farinati F, Russo FP
Medicina 2023
LncRNA AL161431.1 predicts prognosis and drug response in head and neck squamous cell carcinoma
Zhou M, Mao M, Yang F, Zhou T, Zhou L, Li Y
Frontiers in Oncology 2023
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
Srivastava N, Usmani SS, Subbarayan R, Saini R, Pandey PK
Frontiers in Oncology 2023
PRMT5 facilitates angiogenesis and EMT via HIF-1α/VEGFR/Akt signaling axis in lung cancer.
Zheng Y, Ji H, Yi W, Chen Z, Hu X, Zhou J, Wang Y, Zheng X
Aging 2023
Breast cancers as ecosystems: a metabolic perspective
Martino F, Lupi M, Giraudo E, Lanzetti L
Cellular and Molecular Life Sciences 2023
The extracellular vesicles targeting tumor microenvironment: a promising therapeutic strategy for melanoma
Li Y, Liu F
Frontiers in immunology 2023
HIF1A-repressed PUS10 regulates NUDC/Cofilin1 dependent renal cell carcinoma migration by promoting the maturation of miR-194-5p.
Luo W, Xu Z, Wang H, Lu Z, Ding L, Wang R, Xie H, Zheng Q, Lin Y, Zhou Z, Li Y, Chen X, Li G, Xia L
Cell & Bioscience 2023
Quantitative phosphoproteomics reveals molecular pathway network alterations in human early-stage primary hepatic carcinomas: potential for 3P medical approach
Zhang Y, Li N, Yang L, Jia W, Li Z, Shao Q, Zhan X
The EPMA Journal 2023
Changes in serum hypoxia-inducible factor-1α and erythropoietin in allergic rhinitis patients: Correlation with the Th inflammatory profile and disease comorbidities
Al-Rasheedi AN, Almaeen AH, Alotaibi AD, Alruwaili AS, Alruwaili SH, Alruwaili WM, Alsakhry AS, Alruwaili GM, ALkuwaykibi HM, Alrawili NN, Alabdullah RZ, Alatwi RS, Taher I, El-Metwally TH
International journal of immunopathology and pharmacology 2023
Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells
Qiu S, Sheth V, Yan C, Liu J, Chacko BK, Li H, Crossman DK, Fortmann SD, Aryal S, Rennhack A, Grant MB, Welner RS, Paterson AJ, Wende AR, Darley-Usmar VM, Lu R, Locasale JW, Bhatia R
Blood 2023
Mitochondrial Metabolism: A New Dimension of Personalized Oncology
Behnam B, Taghizadeh-Hesary F
Cancers 2023
Hypoxia-inducible-factors differentially contribute to clinical disease and the control of viral replication during RSV infection
Morris DR, Qu Y, Jones-Hall YL, Ivanciuc T, Liu T, Garofalo RP, Casola A
2023
Exosomes as a Nano-Carrier for Chemotherapeutics: A New Era of Oncology
Araldi RP, Delvalle DA, da Costa VR, Alievi AL, Teixeira MR, Dias Pinto JR, Kerkis I
Cells 2023
Correlation analysis of hemoglobin, albumin, lymphocyte, platelet score and platelet to albumin ratio and prognosis in patients with lung adenosquamous carcinoma
Zhang T, Liu W, Xu C
Frontiers in Oncology 2023
A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells
Venkateswaran G, McDonald PC, Chafe SC, Brown WS, Gerbec ZJ, Awrey SJ, Parker SJ, Dedhar S
Molecular cancer therapeutics 2023
Pharmacologic Ascorbate and DNMT Inhibitors Increase DUOX Expression and Peroxide-Mediated Toxicity in Pancreatic Cancer
Steers GJ, O\u2019Leary BR, Du J, Wagner BA, Carroll RS, Domann FE, Goswami PC, Buettner GR, Cullen JJ
Antioxidants 2023
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer
Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M
Molecular Cancer 2023
Peptidergic Systems as Antitumor Targets: A Right Direction to Fight Cancer?
Rodríguez FD, Coveñas R
Cancers 2023
Editorial: Hypoxia, oxidative stress, and endocrine cancers
Duvillié B, Jockers R
Frontiers in Endocrinology 2023
Controlling pericellular oxygen tension in cell culture reveals distinct breast cancer responses to low oxygen tensions
Rogers ZJ, Colombani T, Khan S, Bhatt K, Nukovic A, Zhou G, Woolston BM, Taylor CT, Gilkes DM, Slavov N, Bencherif SA
2023
FNIP1 abrogation promotes functional revascularization of ischemic skeletal muscle by driving macrophage recruitment
Sun Z, Yang L, Kiram A, Yang J, Yang Z, Xiao L, Yin Y, Liu J, Mao Y, Zhou D, Yu H, Zhou Z, Xu D, Jia Y, Ding C, Guo Q, Wang H, Li Y, Wang L, Fu T, Hu S, Gan Z
Nature Communications 2023
Factor-inhibiting HIF (FIH) promotes lung cancer progression
García-del Río A, Prieto-Fernández E, Egia-Mendikute L, Antoñana-Vildosola A, Jimenez-Lasheras B, Lee SY, Barreira-Manrique A, Zanetti SR, de Blas A, Velasco-Beltrán P, Bosch A, Aransay AM, Palazon A
JCI Insight 2023
Development and validation of a combined hypoxia- and metabolism-related prognostic signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma
Wu X, Xie W, Gong B, Fu B, Chen W, Zhou L, Luo L
Frontiers in Oncology 2023
Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs
Shao S, Miao H, Ma W
Frontiers in immunology 2023
Hypoxia-induced PLOD2 promotes clear cell renal cell carcinoma progression via modulating EGFR-dependent AKT pathway activation
Liu T, Xiang W, Chen Z, Wang G, Cao R, Zhou F, Meng Z, Luo Y, Chen L
Cell Death and Disease 2023
Interaction and Collaboration of SP1, HIF-1, and MYC in Regulating the Expression of Cancer-Related Genes to Further Enhance Anticancer Drug Development
Kimura K, Jackson TL, Huang RC
Current issues in molecular biology 2023
Protein kinase B/AKT phosphorylates hypoxia-inducible factor-3α1 in response to insulin, promoting cell growth and migration
Nguyen TV, Bergmann U, Kietzmann T, Mennerich D
Frontiers in Cell and Developmental Biology 2023
Regulation of CMGC kinases by hypoxia.
Kim K, Lee SB
BMB Reports 2023
NLRP3 and cancer: Pathogenesis and therapeutic opportunities.
Tengesdal IW, Dinarello CA, Marchetti C
Pharmacology & Therapeutics 2023
AMPK-HIF-1α signaling enhances glucose-derived de novo serine biosynthesis to promote glioblastoma growth.
Yun HJ, Li M, Guo D, Jeon SM, Park SH, Lim JS, Lee SB, Liu R, Du L, Kim SH, Shin TH, Eyun SI, Park YY, Lu Z, Lee JH
Journal of experimental & clinical cancer research : CR 2023
Mechanisms of Breast Cancer Stem Cell Specification and Self-Renewal Mediated by Hypoxia-Inducible Factor 1
Semenza GL
Stem Cells Translational Medicine 2023
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges.
Yuan X, Ruan W, Bobrow B, Carmeliet P, Eltzschig HK
Nature reviews. Drug discovery 2023
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance
Yao L, Wang Q, Ma W
Cancers 2023
SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma
Daley BR, Sealover NE, Sheffels E, Hughes JM, Gerlach D, Hofmann MH, Kostyrko K, Mair B, Linke A, Beckley Z, Frank A, Dalgard C, Kortum RL
2023
Exploiting the DNA Damage Response for Prostate Cancer Therapy
Stracker TH, Osagie OI, Escorcia FE, Citrin DE
Cancers 2023
The exploration of mitochondrial‐related features helps to reveal the prognosis and immunotherapy methods of colorectal cancer
Xie Y, Jiang H
EMBO reports 2023
Sesquiterpenes and Sesquiterpene Derivatives from Ferula: Their Chemical Structures, Biosynthetic Pathways, and Biological Properties
Wang J, Zheng Q, Wang H, Shi L, Wang G, Zhao Y, Fan C, Si J
Antioxidants 2023
'Slicing' glioblastoma drivers with the Swiss cheese model.
Teran Pumar OY, Lathia JD, Watson DC, Bayik D
Trends in Cancer 2023
MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression
Fu Y, Mackowiak B, Feng D, Lu H, Guan Y, Lehner T, Pan H, Wang X, He Y, Gao B
Gut 2023
A Potential “Anti-Warburg Effect” in Circulating Tumor Cell-mediated Metastatic Progression?
Jiang Z, He J, Zhang B, Wang L, Long C, Zhao B, Yang Y, Du L, Luo W, Hu J, Hong X
Aging and Disease 2023

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Blogged by 1
Posted by 9 X users
On 1 Facebook pages
Referenced in 1 Wikipedia pages
214 readers on Mendeley
See more details